ONC
BeiGene, Ltd. American Depositary Shares
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
20% more call options, than puts
Call options by funds: $27.1M | Put options by funds: $22.6M
10% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 31
4% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 75
0% more funds holding
Funds holding: 223 [Q3] → 223 (+0) [Q4]
0.22% less ownership
Funds ownership: 3.72% [Q3] → 3.5% (-0.22%) [Q4]
23% less capital invested
Capital invested by funds: $10.4B [Q3] → $8.06B (-$2.35B) [Q4]
40% less funds holding in top 10
Funds holding in top 10: 10 [Q3] → 6 (-4) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$313
17%
upside
Avg. target
$331
24%
upside
High target
$348
30%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Macquarie Tony Ren 0% 1-year accuracy 0 / 1 met price target | 17%upside $313 | Outperform Maintained | 28 Feb 2025 |
Citizens Capital Markets Matthew Carletti 83% 1-year accuracy 49 / 59 met price target | 30%upside $348 | Market Outperform Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 3 articles about ONC published over the past 30 days
Neutral
Business Wire
1 hour ago
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell l.

Positive
Benzinga
3 weeks ago
China-Based Biotech BeiGene Scores FDA Approval For Tevimbra/Chemo Combo For Untreated Patients With Esophageal Cancer
On Tuesday, BeiGene Ltd ONC announced FDA approval for Tevimbra (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1).

Neutral
Business Wire
3 weeks ago
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). “The approval of TEVI.

Positive
Seeking Alpha
1 month ago
BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025
BeiGene is a BUY due to Tevimbra's approval and Brukinsa's growing sales, leading to anticipated positive earnings in 2025. Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively, with a 78% and 55% increase, positioning BeiGene for profitability. BeiGene announced a name change to BeOne Medicines, transitioning from historical losses to profitability, and potentially attracting new buyers.

Neutral
24/7 Wall Street
1 month ago
The Billionaire Baker Brothers Just Made This Big Biotech Stock Move
If you're interested in biotechnology stocks, billionaires Julian and Felix Baker are the ones to turn to.

Neutral
Zacks Investment Research
1 month ago
BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for BeiGene (ONC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Neutral
Seeking Alpha
1 month ago
BeiGene, Ltd. (ONC) Q4 2024 Earnings Call Transcript
BeiGene, Ltd. (NASDAQ:ONC ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Dan Maller - Head, Investor Relations John Oyler - Co-Founder, Chairman & Chief Executive Officer Matt Shaulis - General Manager, North America Lai Wang - Global Head, R&D Aaron Rosenberg - Chief Financial Officer Conference Call Participants Kelly Shi - Jefferies Sean Laaman - Morgan Stanley & Co. Andrew Berens - Leerink Partners Jessica Fye - JPMorgan Yigal Nochomovitz - Citigroup Reni Benjamin - Citizens JMP Ziyi Chen - Goldman Sachs & Co Operator Good day, everyone.

Neutral
Business Wire
1 month ago
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced financial results and corporate updates from the fourth quarter and full year 2024. “Our fourth quarter and full year results demonstrate our tremendous growth as a global oncology powerhouse, reinforced by the continued success of BRUKINSA and the development of one of the most prolific solid tumor pipeline.

Neutral
Business Wire
1 month ago
BeiGene to Present at Upcoming Investor Conferences
SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Company will participate in fireside chats at two upcoming investor conferences: TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 am ET; and Leerink Partners Global Biopharma Conference on Monday, March 10, 2025 at 1:00 pm ET Live webcasts of these events can be accessed.

Positive
Zacks Investment Research
1 month ago
BeiGene (ONC) Soars 3.2%: Is Further Upside Left in the Stock?
BeiGene (ONC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Charts implemented using Lightweight Charts™